Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir

Figure 1 Flow diagram of study participants. LMA: Lamivudine; ADV: Adefovir; LdT: Telbivudine; HBV: High hepatitis B virus; HBeAg: Hepatitis Be antigen.

Figure 2 Proportion of patients with undetectable serum hepatitis B virus DNA (< 12 IU/mL) over time. ¹Undetectable < 12 IU/mL. LAM: Lamivudine; ADV: Adefovire; HBV: High hepatitis B virus; LdT: Telbivudine; PCR: Polymerase chain reaction.

Figure 3 Mean hepatitis B virus DNA levels over time in the two groups. LAM: Lamivudine; ADV: Adefovire; HBV: Hepatitis B virus; LdT: Telbivudine.

Figure 4 Mean reduction of serum hepatitis B virus DNA levels from baseline. Mean hepatitis B virus (HBV) DNA (log₁₀ IU/mL) were plotted over time. Error bars indicate the standard deviation (^aP value < 0.05). LAM: Lamivudine; ADV: Adefovire; LdT: Telbivudine.

Figure 5 Estimated glomerular filtration rate over time in the two groups (A), and proportion of patients with estimated glomerular filtration rate ≥ 90 mL/min per 1. 73 m² at baseline and week 48 (B). LAM: Lamivudine; ADV: Adefovire; HBV: High hepatitis B virus; LdT: Telbivudine. GFR: Glomerular filtration rate

Figure 6 Serial changes of mean serum hepatitis B virus DNA levels. Serum hepatitis B virus DNA levels decreased significantly not only from baseline to 12 wk but also from 12 wk to 24 wk in the LdT + ADV group. LAM: Lamivudine; ADV: Adefovire; HBV: High hepatitis B virus; LdT: Telbivudine.